Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Description

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

Conditions

Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease

Study Overview

Study Details

Study overview

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Condition
Alzheimer's Disease
Intervention / Treatment

-

Contacts and Locations

Columbus

The Ohio State University, Columbus, Ohio, United States, 43210

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subjects must meet the standard clinical criteria of the syndromes of interest
  • * All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10.
  • * Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment.
  • * Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week.
  • * Subjects must have visual and auditory acuity adequate for testing.
  • * Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment.
  • * active medical disorder that could preclude participation in this protocol
  • * Women who are pregnant or are breast feeding
  • * severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan).
  • * Subjects in whom English is not the 1st language
  • * Subjects with educational level less than 12 years
  • * Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Douglas Scharre,

Douglas W Scharre, MD, PRINCIPAL_INVESTIGATOR, Ohio State University

Study Record Dates

2024-12